Editorial: Old Problems and New Solutions in Pediatric Pulmonology

Abstract

The series on pediatric pulmonology continues in this issue of the Journal, with four manuscripts that illustrate the new problems of our burgeoning speciality [1–4]. These are how the management of old problems (in this case TB) is being transformed by cutting edge science [1]; how the application of new technologies are creating challenging problems (congenital lung disease) [2]; and how new technologies are transforming the lives of children (neuromuscular disease and NIV) and taking mechanical ventilation, what used to be the prerogative of intensive care into the home, transforming the prognosis of children [3, 4]. However, as we shall see, the more the speciality advances, the more the basic truths we learned as students remain the bedrock of our practice. Old disease, new technology: TB, the captain of the men of death, used to be simple – the tuberculin skin test, sputum (or other biological sample) microscopy and culture, and evidence based treatment with quadruple therapy for 2 mo, and rifampicin and isoniazid for a further 4 mo. Problem solved, even though diagnostics and determining sensitivities might take weeks – treatment could confidently be started while waiting. In children, admittedly diagnosis often had to be on clinical suspicion, because it was difficult to obtain samples. Enter the Dragon! Or rather, multidrug-resistant TB, extremely drug-resistant TB and totally drug resistant TB [5]. Perspectives have had to change rapidly; now we need rapid diagnosis and rapid sensitivity testing, for fear of starting drugs to which the organism is resistant, effectively but inadvertently proposing a single agent regime which will lead to worse problems of drug resistance. The problem has been made worse with the advent of HIVand the consequent worsening of the manifestations of TB. The modern approach is firstly to use novel tests to obtain specimens, such as sputum induction which can be taken in very young babies, and the string test. The second approach is newer microscopy and culture techniques, and specific molecular diagnostics, which are reviewed [1]. Molecular tests not merely detect MTB rapidly in sputum or gastric aspirates, but also allow drug sensitivities to be determined, a major management advance. The future will undoubtedly include molecular handprints on blood samples, as sophisticated techniques become cheaper and more accessible. New technology, new problems: Increased monitoring of pregnant women with ultrasound scanning, and increasingly MRI, has identified abnormalities which previously passed us by. Congenital lung malformations come into just this category. In this issue, a simple clinical classification of congenital thoracic malformations (CTM), which is applicable preand post-natally, is described. However, description is one thing, evidence based management is another. How should you counsel a woman with a fetus with a large CTM at 20 wk of the pregnancy? If the baby is born well, what further imaging should be done and when? What is the risk of complications, and should well babies be submitted to surgery to reduce the risk? And when should surgery be performed? Finally, the biggest elephant in the room, what is the risk of primary lung malignancy in a baby with a CTM? High risk groups can be delineated, but most babies with CTMs are low risk. * Andrew Bush A.Bush@rbht.nhs.uk